Jefferies, TD Cowen, Stifel and Guggenheim acted as joint book running managers for the offering.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics price target raised to $118 from $108 at Deutsche Bank
- Apogee Therapeutics price target raised to $160 from $130 at Guggenheim
- Apogee Therapeutics price target raised to $125 from $95 at Citi
- Apogee Therapeutics price target raised to $130 from $89 at Canaccord
- Apogee Therapeutics: Strong Phase IIa IL‑13 Data Support Buy Rating and Long-Term Upside in Atopic Dermatitis